Literature DB >> 15857131

Molecular dynamics simulation of the ligand binding domain of farnesoid X receptor. Insights into helix-12 stability and coactivator peptide stabilization in response to agonist binding.

Gabriele Costantino1, Antonio Entrena-Guadix, Antonio Macchiarulo, Antimo Gioiello, Roberto Pellicciari.   

Abstract

The dynamic changes which take place in the ligand binding domain (LBD) of farneosid X receptor (FXR) in response to agonist binding and in the presence of coactivator peptides were studied with nanosecond time-scale molecular dynamics. Four different systems were analyzed, including the holo-LBD complexed with 6ECDCA, the holo-LBD in the presence of two coactivator peptides, and two artificial apo forms, with and without coactivator peptides. Our results revealed a detailed picture of the differential micro- and macromodifications occurring in the LBD in the presence or not of the agonist molecule and the coactivator peptides. In the apo simulation a major conformational change took place in the crucial helix 12, while the holo-LBD was globally stabilized by the ligand. When the coactivator peptides were included in the simulation, a clear agonist-induced stabilization was observed for the canonical peptide. Interestingly, the second peptide was released from the holo-LBD while it was kept bound in the apo simulation. The present results provide a molecular basis for the understanding the role played by the bile acid agonist in receptor stabilization and enhanced cofactor recruitments.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15857131     DOI: 10.1021/jm049182o

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  7 in total

1.  Pharmacophore model for bile acids recognition by the FPR receptor.

Authors:  Cristina Ferrari; Antonio Macchiarulo; Gabriele Costantino; Roberto Pellicciari
Journal:  J Comput Aided Mol Des       Date:  2006-09-14       Impact factor: 3.686

2.  The membrane protein ATPase class I type 8B member 1 signals through protein kinase C zeta to activate the farnesoid X receptor.

Authors:  Tamara Frankenberg; Tamir Miloh; Frank Y Chen; Meena Ananthanarayanan; An-Qiang Sun; Natarajan Balasubramaniyan; Irwin Arias; Kenneth D R Setchell; Frederick J Suchy; Benjamin L Shneider
Journal:  Hepatology       Date:  2008-12       Impact factor: 17.425

3.  Conformational dynamics of human FXR-LBD ligand interactions studied by hydrogen/deuterium exchange mass spectrometry: insights into the antagonism of the hypolipidemic agent Z-guggulsterone.

Authors:  Liping Yang; David Broderick; Yuan Jiang; Victor Hsu; Claudia S Maier
Journal:  Biochim Biophys Acta       Date:  2014-06-18

4.  The conformational feasibility for the formation of reaching dimer in ASV and HIV integrase: a molecular dynamics study.

Authors:  Sangeetha Balasubramanian; Muthukumaran Rajagopalan; Ravi Shankar Bojja; Anna Marie Skalka; Mark D Andrake; Amutha Ramaswamy
Journal:  J Biomol Struct Dyn       Date:  2016-11-28

5.  Dual farnesoid X receptor/TGR5 agonist INT-767 reduces liver injury in the Mdr2-/- (Abcb4-/-) mouse cholangiopathy model by promoting biliary HCO⁻₃ output.

Authors:  Anna Baghdasaryan; Thierry Claudel; Judith Gumhold; Dagmar Silbert; Luciano Adorini; Aldo Roda; Stefania Vecchiotti; Frank J Gonzalez; Kristina Schoonjans; Mario Strazzabosco; Peter Fickert; Michael Trauner
Journal:  Hepatology       Date:  2011-10       Impact factor: 17.425

6.  In Silico Predictions of Endocrine Disruptors Properties.

Authors:  Melanie Schneider; Jean-Luc Pons; Gilles Labesse; William Bourguet
Journal:  Endocrinology       Date:  2019-11-01       Impact factor: 4.736

7.  Discovery of Natural Products as Novel and Potent FXR Antagonists by Virtual Screening.

Authors:  Yanyan Diao; Jing Jiang; Shoude Zhang; Shiliang Li; Lei Shan; Jin Huang; Weidong Zhang; Honglin Li
Journal:  Front Chem       Date:  2018-04-30       Impact factor: 5.221

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.